We are live on ! Find out more
JSPR icon

Jasper Therapeutics

65 hedge funds and large institutions have $69.5M invested in Jasper Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

24% more capital invested

Capital invested by funds: $56.1M → $69.5M (+$13.4M)

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

3.56% less ownership

Funds ownership: 86.87%83.31% (-3.6%)

4% less funds holding

Funds holding: 6865 (-3)

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

23% less call options, than puts

Call options by funds: $232K | Put options by funds: $302K

Holders
65
Holders Change
-3
Holders Change %
-4.41%
% of All Funds
0.86%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
17
Increased
17
Reduced
17
Closed
20
Calls
$232K
Puts
$302K
Net Calls
-$70K
Net Calls Change
-$154K

JSPR Hedge Fund Activity: Q2 2025 in Review

65 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2025, worth a combined $69.5M — up 24% from $56.1M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of JSPR and 17 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 17 added.

The largest buyer was Kingdon Capital Management, adding an estimated $959K. The largest seller was BlackRock, cutting an estimated $2.77M.

  • 65 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2025, down from 68 in Q1 2025.
  • Funds reported $69.5M of Jasper Therapeutics stock for Q2 2025, up 24% quarter-over-quarter.
  • 17 funds opened new Jasper Therapeutics positions in Q2 2025 and 20 closed out, a net change of -3 holders.
  • The largest Jasper Therapeutics buyer in Q2 2025 was Kingdon Capital Management, an estimated $959K added.
  • The largest Jasper Therapeutics seller in Q2 2025 was BlackRock, an estimated $2.77M sold.

Based on aggregated 13F filings for Q2 2025.